---
document_datetime: 2025-09-25 10:42:00
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sugammadex-adroiq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sugammadex-adroiq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.470496
conversion_datetime: 2025-12-25 02:47:58.295103
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sugammadex Adroig

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | A.ADMINISTRATIVECHANGES-A.1 Change | 23/09/2025                          |                                          | SmPC,                           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | in the name and/or address of the marketing authorisation holder - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     | Labelling and PL   | EMA/VR/0000297355   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|---------------------|
| Variation type IB / | This was an application for a group of variations. B.I.a.1 Change in themanufacturer of a starting material/reagent/intermediate used in themanufacturingprocessof the active substanceorchangeinthemanufacturer (includingwhererelevantquality control testing sites)of the activesubstance,where noPh.Eur.Certificate ofSuitability is part of the approveddossier-B.I.a.1.z Other variation - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension orintroduction of a re- test period/storage period supported by real time data - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of theactivesubstance-Accepted B.I.a.1Changeinthemanufacturerofa startingmaterial/reagent/intermediateused in the manufacturing process of the active substanceorchangeinthemanufacturer | 04/08/2025 | N/A |                    | EMA/VR/0000282615   |
|                     | (including where relevant quality control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |                    |                     |
|                     | testingsites)of theactivesubstance,where                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |                    |                     |

<div style=\"page-break-after: always\"></div>

|                                     | no Ph. Eur. Certificate of Suitability is part of the approved dossier-B.I.a.1.z Other variation - Accepted B.I.a.3 Change in batch size (including batch sizeranges)of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted A.ADMINISTRATIVE CHANGES-A.4 Change inthenameand/oraddressof:a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate used in themanufacture of the active substance (where specified in the technical dossier)where noPh.Eur.Certificate of Suitability is part of the approved dossier; or a manufacturer of a novelexcipient(where specified in the technical dossier) - Accepted   |            |      |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation typeIB/ EMA/VR/0000257364 | C.I.2Change(s)in theSummaryofProduct Characteristics,LabellingorPackageLeaflet of ageneric/hybrid/biosimilarmedicinal products following assessment of the same change for the reference product-C.I.2.a Implementation of change(s) for which no new additional data is required to be                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/03/2025 | SmPC |

<div style=\"page-break-after: always\"></div>

|                                          | submittedbytheMAH-Accepted C.1.2.a-To update section 4.8 of the SmPC for Hypersensitivity following assessment of the same change for the reference product Bridion100mg/mL solutionfor injection.                                                                                                                                                            |            |     |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA_IN / EMA/VR/0000251824 | C.I.3Change(s)in theSummary of Product Characteristics,Labelling orPackageLeaflet of humanmedicinalproducts intended to implementtheoutcomeofaprocedure concerningPSURorPASS,ortheoutcome of theassessmentdonebythecompetent authorityunderArticles45or46of Regulation1901/2006-C.1.3.a Implementation of wording agreed by the competent authority - Refused | 27/02/2025 | N/A |